Extending the shelf life of fruit: Ugandan entrepreneurs Sandra Namboozo and Samuel Muyita in top 10 innovators of the Young Inventors Prize 2025 awarded by the European Patent Office (EPO)
Food loss and waste account for 8-10% of annual global greenhouse gas emissions, according to the UNFCCC
Namboozo and Muyita's sachets keep fruit fresh by up to extra 30 days, reducing waste and boosting farmer incomes
The pair are among top ten innovators for the Young Inventors Prize, awarded by the European Patent Office (EPO) on 18 June 2025
MUNICH, May 18, 2025 /PRNewswire/ -- Over 1 billion tonnes of food are wasted annually, while 783 million people face hunger, according to the United Nations Framework Convention on Climate Change (UNFCCC). Ugandan entrepreneurs Sandra Namboozo (26) and Samuel Muyita (27), founders of Karpolax, have developed a plant-based sachet that extends the shelf life of fresh fruit by up to 30 days. Their sustainable, biodegradable preservation solution has earned them a place in top 10 innovators in the Young Inventors Prize 2025, known as Tomorrow Shapers, which recognises young inventors tackling global challenges. They were selected from 450 candidates by an independent jury.
Sustainable preservation and fresher produce
Despite the steady increase in the global population, around 40% of all food produced does not reach the market, according to the World Wildlife Fund.
Namboozo and Muyita both grew up in farming families and saw first-hand the challenges of post-harvest losses, which have a devastating impact on the profit of small-scale farmers. Determined to find a natural and more affordable alternative to synthetic preservers, they developed sachets, which release a blend of plant-derived volatile organic compounds (VOCs) to slow ripening and prevent spoilage. The compounds – extracted from cloves, lemongrass, eucalyptus and wintergreen – inhibit ethylene production, the natural gas responsible for fruit ripening, and offer protection against mould, fungi and bacteria. Their solution allows for the controlled, sustained release of these compounds, tailored to different fruit types, thereby providing a biodegradable alternative to conventional artificial preservers.
Pilot tests conducted with Uganda's National Agricultural Research Organization showed that mangoes stored with the sachets remained fresh for 33 days, while those without them lasted only 11 days. The sachets have since been successfully used on bananas, apples, and oranges. With an affordable price point, Karpolax's sachets are particularly suited to smallholder farmers and local markets, offering a cost-effective and locally accessible way to reduce food waste and increase earnings.
Protecting innovation for lasting impact
"Farmers are one of our biggest customer groups. We wanted to use our knowledge and technical skills to develop something that would not just end on a paper in a lab but really be used by somebody," explains Namboozo.
The duo met while studying at Makerere University in Kampala, where they quickly bonded over a shared ambition to reduce food waste. They launched Karpolax in 2020 and aim to expand its reach across Africa, targeting Kenya, Rwanda and beyond. "Starting from zero, you need to source for that funding yourself. We had some supervisors from the university who supported us and made us feel confident that we could succeed," added Muyita.
By 2023, Karpolax had already worked with over 100 farmers, 20 exporters and 250 market vendors. The company is now expanding its product line to include sachets for pineapples, capsicum and berries.
The Young Inventors Prize celebrates worldwide innovators 30 and under using technology to address global challenges posed by the United Nations Sustainable Development Goals (SDGs). Namboozo and Muyita's work supports SDG 2 (Zero Hunger) by reducing post-harvest losses and SDG 12 (Responsible Consumption and Production) by promoting sustainable food preservation practices.
The prizes of the 2025 edition will be announced during a ceremony livestreamed from Iceland on 18 June 2025.
Find more information about the invention's impact, the technology and the inventor's story here.About the Young Inventors Prize
Aimed at individuals 30 and under, the Young Inventors Prize showcases the transformative power of youth-driven solutions and recognises the remarkable young people paving the way to a more sustainable future. Established in 2022, trophies were first handed out during the European Inventor Award ceremony. From 2025 onwards, the Prize will move up a gear with its own dedicated event, held separately from the Award. Among the 10 Tomorrow Shapers selected for each edition, three will be awarded a special prize: World Builders, Community Healers, and Nature Guardians. In addition, a People's Choice winner, voted by the public online, will be revealed. Each Tomorrow Shaper will receive EUR 5 000, the three special prize winners will each receive an extra EUR 15 000. The People's Choice winner will be awarded an additional EUR 5 000. Read more on the Young Inventors Prize eligibility and selection criteria.
About the EPO
With 6,300 staff members, the European Patent Office (EPO) is one of the largest public service institutions in Europe. Headquartered in Munich with offices in Berlin, Brussels, The Hague and Vienna, the EPO was founded with the aim of strengthening co-operation on patents in Europe. Through the EPO's centralised patent granting procedure, inventors are able to obtain high-quality patent protection in up to 46 countries, covering a market of some 700 million people. The EPO is also the world's leading authority in patent information and patent searching.
View original content:https://www.prnewswire.com/news-releases/extending-the-shelf-life-of-fruit-ugandan-entrepreneurs-sandra-namboozo-and-samuel-muyita-in-top-10-innovators-of-the-young-inventors-prize-2025-awarded-by-the-european-patent-office-epo-302458082.html
SOURCE European Patent Office (EPO)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fast Company
5 hours ago
- Fast Company
China is catching up to the U.S. in pharmaceuticals, but it's not too late to turn that around
A decade ago, China had just a few hundred pharmaceutical drugs actively in development. Today, China has thousands of drugs in active development and is continually increasing investment to make even more. This transformation was not, however, a foregone conclusion: China faced incredibly high barriers to growing its pharmaceutical industry including weak research investment and a highly fragmented market of small drug development firms. However, through engineering an environment conducive to pharma innovation, China went from developing 2% of all drugs globally to 25%. Over the same period, the U.S. decreased its share from 45% to 36%, according to Evaluate's internal data. A boost in funding and regulatory changes opened the door, but access to the right talent has taken China across the threshold into a pharmaceutical golden age. Scientists from China and other parts of Asia used to come to the U.S. to work for the biggest drug companies and with the brightest minds. Now, many experts are heading East to fill China's labs, and this return began well before the current administration took office. The result? A huge increase in the quality and quantity of novel Chinese medicines in development. Licensing deals To understand the threat China poses, look to major drug companies' product portfolios. Increasingly, instead of acquiring homegrown innovations, pharma giants including Novo Nordisk, Merck & Co., AstraZeneca, and most recently Pfizer are entering into high-profile licensing deals with Chinese firms. In 2024, 31% of big pharma licensing deals involved a Chinese biotech and that number is projected to grow this year. China now offers a dizzyingly abundant source of innovative, high-quality therapies at—by pharma standards—reasonable prices. Could the U.S. pharmaceutical industry, long a shining example of innovation on the world stage, soon be eclipsed? While China's pharma industry is close to becoming the world leader, the U.S. still holds key advantages to maintain dominance. Where China Has The U.S. Beat There are three hot spots of innovation in next-generation therapies where China's lead is becoming pronounced: Bispecific Antibodies ('Bispecifics): Engineered antibodies that bind to two different targets simultaneously, offering a novel way to fight cancers. They garnered billions of dollars in sales last year and 56% of those currently in development originated in China, according to Evaluate's internal data. Antibody-Drug Conjugates ('ADCs'): These antibodies deliver a highly potent chemotherapy drug directly to cancer cells. The ADC market is projected to reach $50B by 2030 and 55% of those currently in development originated in China. Chimeric Antigen Receptor T-Cells ('CAR-Ts'): T-cells modified to recognize and kill cancer cells. The CAR-T market is expected to reach over $21B by 2030 and 51% of therapies currently in development originated in China. GLP-1s Notably, despite the increasingly crowded nature of the obesity and diabetes space, Evaluate's internal data shows 46% of GLP-1 therapies in development are from Chinese sponsors. Merck, for example, made its first move into the obesity space not by developing its own drug but by licensing a Chinese GLP-1 pill late last year. Questions remain, though, about whether Chinese players can catch Western pharma leaders which have a huge head start in the obesity space. Realistically, it's unlikely that the U.S.—or any other country—will beat China in these top three areas, though many of these Chinese drugs will be acquired by U.S. companies before they reach the market. Despite China's formidable drug development pipeline, the nation still faces outsized challenges around financing innovative and late stage trials, multiple competitors racing to patent highly similar versions of a single drug, and pricing pressure from generic versions of drugs whose patents have expired—all of which might stall China's influence. U.S. Pharma's Secret Weapons While China ramps up novel cancer treatments, the U.S. remains a powerhouse with the infrastructure, academic institutions, and regulatory systems that will ensure it continues to play a critical role in the global market. While the U.S. does not have an overwhelmingly large global share of the development of any kind of drug, it still has a significant portion of many of the largest, and most exciting types. These include: Radiopharmaceuticals: Radioactive molecules injected into the body for both targeted cancer irradiation and medical imaging. They're already a multi-billion-dollar market, and the U.S. controls 40% of those currently in development. Traditional Small Molecules: The foundation of medicine (Lipitor is an example), these drugs are still extremely widely used and the U.S. controls 37% of those currently in development. Discovery advantages Beyond dominating in these two treatment types, the U.S. has a few key advantages that will be its saving grace in the competition for biopharma dominance. The United States' ace-in-the-hole is making initial scientific discoveries. It is still the best at finding new disease processes and ways of designing drugs while China's strength is iterating on already-established successes. Take the aforementioned ADCs and CAR-Ts: these innovations were discovered in U.S. labs and China has run with tweaked versions. While China is starting to break ground on developing new biology, the U.S. still has the drug discovery edge. Secondly, U.S. investors are willing to take risks. While the Chinese state is working to create a strong environment for biotechs, private investors in China are more risk-averse than their Western counterparts. So, there is opportunity in the U.S. to support potentially high-growth areas, such as cell and gene therapy. Thirdly, don't underestimate manufacturing. Since the announcement of potential tariffs hitting the pharma industry, a number of large drug companies have announced huge investment in their U.S. manufacturing sites. Many of these were almost certainly in the cards already but more investment in the U.S. will help bolster the wider industry. The Biosecure Act also supports this effort, enforcing stricter regulations on the supply chain. Innovation insurance Finally, dealmaking is innovation insurance. U.S. big pharma is well used to sourcing innovation and drug development programs through dealmaking, so one can argue that simply extending their gaze East to draw from the new pool in China is not such a shift anyway. Many, if not most, of the next generation therapies are likely to be acquired from abroad before completing their late-stage trials in the U.S. and reaching the market. Continued international licensing will ultimately benefit the bottom lines of American companies. China's genie is out of the bottle and there is no doubt that the country's ability to develop innovative drugs will continue to thrive. As the landscape diversifies, both countries will play crucial roles in advancing pharmaceutical innovation. Both the U.S. and China hold unique advantages; now is the moment America can reinvest in theirs to come out on top.
Bloomberg
6 hours ago
- Bloomberg
How AI and Charter Schools Could Close the Tutoring Gap
The greatest school in history isn't Oxford, Cambridge, Harvard or any other university you know. And no matter how hard you try, your kids won't get in. Why? Partly because it was so selective it only admitted one student — but mainly because it closed in 336 BC. For me, Aristotle's seven-year tutelage of Alexander is the education against which all others should be judged (after all, more than 2,300 years later we still refer to the lone pupil as 'The Great'). It's the ultimate testament to the power of tutoring — a power that artificial intelligence is poised to unlock. The problem with tutoring is it can't scale. Or it couldn't. Because even as we're besieged by concerns that AI-aided plagiarism is destroying education, we're starting to see evidence that AI-enabled tutoring might supercharge it. Getting the technology right, though, will require lots of real-life experimentation. While there's a limit to how much our traditional public school system allows for this kind of test-and-learn approach, this need creates an opportunity for the country's growing crop of charter schools to make a unique contribution to the future of education.
Yahoo
8 hours ago
- Yahoo
Clarivate Identifies Radioligand Therapy Innovators as Companies to Watch in the Future of Precision Oncology
New Report Highlights Emerging Leaders Advancing Next-generation Radiopharmaceuticals, Reshaping Cancer Care Through Targeted Innovation and Strategic Growth LONDON, June 16, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the release of a new Companies to Watch report, Radioligand Innovators Ushering in a New Era of Precision Oncology. The report spotlights pioneering companies that are redefining the drug discovery and development landscape through advancements in radioligand therapies (RLTs)—a rapidly evolving class of therapeutics that combines nuclear medicine with precision-targeted biotechnology to treat cancer with heightened specificity. Drawing on proprietary data, expert analysis and insights into therapeutic benefit, financing activity and R&D momentum, the report highlights why these organizations are considered high-impact innovators. This latest edition follows previous Companies to Watch reports focused on RNA-based technologies, artificial intelligence/ machine learning (AI/ML), next-generation gene-editing and antibody-drug conjugates (ADCs). Radioligand therapies represent one of the most promising frontiers in oncology, offering highly specific delivery of radioactive isotopes to tumor cells while minimizing damage to healthy tissue. These agents are rapidly gaining momentum as both scientific breakthroughs and strategic investments accelerate across the global pharmaceutical landscape. Michael Ward, Global Head of Thought Leadership, Life Sciences & Healthcare, Clarivate, said: "Radioligand therapies are emerging as a cornerstone of precision oncology, combining decades of research in nuclear medicine with the latest innovations in biotechnology. This report identifies the innovators that are pushing the boundaries of what's possible in cancer care — and highlights the market, scientific and strategic signals that make them companies to watch." David Bejker, Chief Executive Officer, Affibody, said: "Radioligand therapies (RLTs) are transforming the promise of precision medicine into reality, enabling treatments that are finely tuned to the unique characteristics of each patient and their tumor, rather than relying on one-size-fits-all solutions. By uniting the precision of targeted drug delivery with the power of radiotherapy, RLTs use tumor-seeking molecules linked to therapeutic radioisotopes to deliver radiation directly to cancer cells, minimizing damage to healthy tissue and opening a new frontier in personalized cancer care." The report offers a detailed view of the evolving RLT landscape, highlighting the science, clinical promise and market momentum behind this precision approach. It profiles emerging innovators; explores key trends in M&A, funding and partnerships; and examines how differentiated R&D strategies and IP positioning set companies apart. The report also addresses challenges in manufacturing and regulation while assessing advances in alpha-emitting isotopes, combination therapies and the infrastructure needed to deliver next-generation radiotherapies at scale. The Radioligand Companies to Watch are: Affibody, founded by researchers at the KTH Royal Institute of Technology and Karolinska Institutet, has a mission of addressing medical needs with pioneering treatments that can improve the lives of patients with serious diseases. As a clinical stage biopharmaceutical company, it has pre-clinical and clinical development programs in oncology and immunology, with a broad product pipeline focused on developing innovative next-generation biopharmaceutical drugs based on its proprietary technology platform, Affibody® molecules. Alpha-9 Oncology is developing and advancing a pipeline of differentiated and highly targeted radiopharmaceuticals as potentially life-improving treatments for various malignancies. The company's bespoke, iterative process leverages the team's deep expertise in modifying peptides, small molecules and small biologics to inform target selection, molecule design, formulation and clinical evaluation. Ariceum Therapeutics was launched after the acquisition of the rights for its lead product, satoreotide (SSO110), from Ipsen, which has remained a shareholder in the company. Satoreotide is a proprietary peptide derivative that binds to somatostatin receptor 2 (SSTR2), which is overexpressed in neuroendocrine tumors and some aggressive cancers. The company is developing radiopharmaceutical theranostic pairs focusing on aggressive tumors such as small-cell lung cancer (SCLC) and Merkel cell carcinoma (MCC). Convergent Therapeutics is developing radioantibodies, by conjugating alpha radionuclides to antibodies that target cancer cells. Its lead candidate, CONV01-α (Ac-225 rosopatamab tetraxetan), is in phase 2 trials for prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). Perspective Therapeutics, a clinical-stage, radiopharmaceutical company, has adopted a theranostic approach using its proprietary chelator technology platform that enables radiolabeling of targeting moieties against cancers with therapeutic isotopes of lead (Pb-212) or diagnostic isotopes such as Ga-68 for high-resolution imaging of uptake or Pb-203 for retention of uptake. The company has also entered into exclusive licensing and patent agreements with academic institutions to broaden its alpha-emitting radiopharmaceutical platform capabilities. PRECIRIX®, founded as a spin-off from Vrije Universiteit Brussel (VUB), is designing and developing radiopharmaceutical theranostics using camelid single-domain antibodies (sdAb) labeled with radiometals against multiple targets. The company's lead program, which targets fibroblast activation protein (FAP), could be a best-in-class alpha-emitting targeted radiotherapy against FAP and has been designed to address FAP-positive tumors. Notable developments shaping the RLT field include high-profile acquisitions — such as Bristol Myers Squibb's $4.1 billion purchase of RayzeBio and AstraZeneca's $2.4 billion acquisition of Fusion Pharmaceuticals — as well as blockbuster therapies like Novartis' PLUVICTO® and LUTATHERA®, which have paved the way for broader adoption. As the global radiopharmaceutical market is projected to surpass $13 billion within the next decade, the companies featured in this report are well-positioned to lead the next wave of therapeutic innovation. To download the full report or learn more, visit here. Methodology for the Companies to Watch ReportClarivate analysts employed a rigorous, multidimensional framework to identify the emerging innovators featured in this Companies to Watch report. Each company was assessed for its ability to address critical scientific, clinical and business challenges within the radioligand therapy space. Key considerations included demonstrated proof of concept, achievement of developmental milestones and positioning within the clinical trial landscape. The evaluation also factored in the strength of collaborations with leading academic and research institutions, the potential to address significant unmet medical needs and the overall burden of disease targeted by each therapy. Financial health was a further determinant, with analysts examining capital raised, investor partnerships, projected runway and prospects for future growth through fundraising or strategic alliances. Finally, each company's intellectual property estate was analyzed to understand the strength and breadth of its innovation pipeline. The assessment was underpinned by insights from Clarivate's trusted proprietary data sources, including Cortellis Competitive Intelligence™, Cortellis Deals Intelligence™, Cortellis Regulatory Intelligence™, Cortellis Clinical Trials Intelligence™, BioWorld™ and OFF-X™ Translational Safety Intelligence, ensuring a holistic view of the companies poised to shape the future of precision oncology. About ClarivateClarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit Media Contact:Catherine DanielDirector, External Communications, Life Sciences & Healthcarenewsroom@ View original content to download multimedia: SOURCE Clarivate Plc
